Increasing Drug Development Burgeoning Market Growth
The global Clostridium difficile infection treatment market was anticipated to be US$ 840 Mn in 2018, and is expected to exhibit a CAGR of 5% during the forecast period. C. difficile is a bacterium that infects colon and causes diarrhea. C. difficile commonly affects adults in hospitals, clinics and in long-term care facilities and typically occurs after the use of antibiotics.
Increase in the consumption of antibiotics and easy availability of generic antibiotics are factors expected to drive the Clostridium difficile infection treatment market growth. Manufacturers are focusing on developments in elective treatments such as immunizations and microbiome therapeutics as an effective treatment approach for Clostridium difficile infection. For instance, Sanofi accessed the efficacy of difficile toxoid vaccine to prevent primary symptomatic C. difficile infection (CDI). Moreover, in emerging economies, outbreaks requiring antibiotic medication are also responsible for increasing incidence of Clostridium difficile infection.
North America Dominating Clostridium difficile Treatment Market
North America is expected to be the dominant region in the Clostridium difficile infection treatment market owing to increasing prevalence of Clostridium difficile infection. Also, increase in research and development activities for developing novel therapies is aiding market growth in the region. For instance, Eravacycline and Omadacycline were recently approved by the US Food and Drug Administration (FDA) in 2019, intended to quell gram-positive pathogens, including Clostridioides difficile (C diff) and non-tuberculosis (TB) mycobacterial infections.
North America holds significant market share in the Clostridium difficile treatment market with 31% of total revenue and is expected to grow at a CAGR of 5.5% in the forecast period. On the other hand, Europe represents second most lucrative region in the Clostridium difficile infection treatment market and is expected to exhibit a CAGR of 5.1% in the forecast period with 28% of market share. Attributed to the presence of domestic players offering generic drugs, Asia Pacific is expected to be a significant revenue generator during the forecast period.
Key Trends Shaping Clostridium difficile Infection Treatment Market
The launch of prophylactic medicines through microbiological approach and novel antibiotics is focused towards reduction in recurrence of C. difficile infection (CDI). Existing treatment choices for CDIs are restricted to antibiotics only. Pharmaceutical organizations are currently concentrating on developing non-antibiotic options, which will provide doctors an alternative treatment choice.
Moreover, a new class of drugs such as microbiome therapeutics is being developed for Clostridium difficile infection treatment and many leading biopharmaceutical companies are actively working on it. This development of new class of drugs would create numerous opportunities for market players and increase the competition level for innovating drugs as better treatment option. For example, Merck’s monoclonal antibody, Zinplava (bezlotoxumab), was approved by FDA, and is the first non-antibiotic option for Clostridium difficile infection.
Increasing use of antibiotics and antimicrobial drugs is increasing the incidences of Clostridium difficile infection, worldwide. Growing incidence of hospital-acquired infections further encourages the use of these high-risk antibiotics. According to CDC study Clostridium difficile caused almost half a million infections among patients in United States in 2015. According to Point Prevalence Survey of Antimicrobial Use in acute care patients by CDC, 50% of the patients in acute care hospitals in the U.S. received more than 2 antibiotics at a time and 23% of them were receiving it for prophylaxis increasing the risk for Clostridium difficile infection.
Key Market Players Focusing on Product Diversification
The Clostridium difficile infection treatment market is characterised as a fragmented market with Merck & Co. Inc., Baxter International Inc., and Sanofi as leading market players. These industries continue to dominate the market for Clostridium difficile infection treatment with increasing investments in research and development, product diversification, and strategic partnerships and acquisitions to enhance product portfolio and customer base.
In Sept 2018, Astellas Pharma Inc. launched Dafclir Tablets 200 mg (generic name: fidaxomicin, “Dafclir”) for Clostridium difficile infection treatment in Japan. Earlier in 2018, Johnson & Johnson completed the acquisition of Actelion Ltd, which enhanced the product portfolio for Clostridium difficile infection treatment. Actelion Ltd developed a drug named Cadazolid that is effective against Clostridium difficile infection.
The growth in the Clostridium difficile infection treatment market is mainly attributed to increasing number of patients suffering from Clostridium difficile infections and growing inclination towards novel class of therapeutics. Strong financial position and new product development are strategies benefiting the key market players in the Clostridium difficile infection treatment market. Companies with research and development capabilities focused on alternative therapies such as vaccines and microbiome therapeutics are expected to positively impact growth of the Clostridium difficile infection treatment market during the forecast period.
Clostridium Difficile Infection Treatment Market - Scope of the Report
Persistence Market Research (PMR) recently published a market study on the global market for Clostridium difficile infection treatment. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the Clostridium difficile infection treatment market. The market study presents exclusive information about how the Clostridium difficile infection treatment market will grow during the forecast period of 2019-2029.
Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. Other information includes epidemiological studies, incidence rate by region and by drug type, which helps in deep understanding of the diseases by researchers, manufactures, and distributors. This information can help readers understand the quantitative growth prospects of the Clostridium difficile infection treatment market during the forecast period.
The study is relevant for manufacturers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Business researcher, shareholders, industry experts can leverage the information and data presented in PMR’s study.
The study also includes statistics as well as facts related to macroeconomics factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the Clostridium difficile infection treatment market. Furthermore, small businesses and new entrants in the Clostridium difficile infection treatment market too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.
Key Segments of the Clostridium difficile Infection Treatment Market
PMR’s study on the Clostridium difficile infection treatment market offers information divided into four important segments - drug type, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Route of Administration
Key Questions Answered in PMR’s Clostridium difficile infection treatment Market Report
Clostridium difficile Infection Treatment Market: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the Clostridium difficile infection treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analyst ensure accuracy and reliability of the conclusions.
Secondary resources referred to analyst during the production of the Clostridium difficile infection treatment market study include statistics from government healthcare organizations, medicines journals, research journals, press release, annual reports, white papers, directories, and databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the Clostridium difficile infection treatment market, and makes PMR’s projection on the growth prospects of the Clostridium difficile infection treatment market more accurate and reliable.